PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals, Inc. (OTCBB: ACCPD), a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand. The terms of the agreement are congruent to the Company's recent license with Norgine for MuGard in Europe. Norgine will now develop, manufacture, and commercialize MuGard in the new territories.

Commenting on the news, Mr. Scott Schorer, CEO of PlasmaTech Biopharmaceuticals stated, "Access is pleased to announce this additional partnership with Norgine, a leading European specialty company, as it further validates our MuGard global growth strategy. With strong international presence, an existing supportive cancer care product portfolio and commitment to providing cancer patients with effective treatments, Norgine is an ideal partner to have as we enter new markets, like Australia and New Zealand."

MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients in the US alone developing the condition each year.